Description
Enhancing ovarian cancer immunogenicity by increasing antitumoral responses using engineered oncolytic vaccines
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02018-04-01$910,350
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2018-04-01(start date) | $910,350 | — | Enhancing ovarian cancer immunogenicity by increasing antitumoral responses using engineered oncolytic vaccine… |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2023-2024-Q1-00119 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $906,525 | FY2024 |
| 236-2020-2021-Q3-00075 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research | $680,850 | FY2021 |
| 236-2019-2020-Q1-01164 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas | $10,000 | FY2020 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2017-2018-Q4-00108 · retrieved 2026-11-14.